CJC-1295 + Ipamorelin: The Complete Stack Guide

What Is the CJC-1295 + Ipamorelin Stack?

CJC-1295 and Ipamorelin are two growth hormone secretagogues that are almost always used together. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog that stimulates the pituitary to release growth hormone over an extended window. Ipamorelin is a GHRP (growth hormone-releasing peptide) that amplifies that pulse and suppresses somatostatin, the hormone that normally puts the brakes on GH release. Together they produce a stronger, more physiologic GH pulse than either peptide does alone.

How Each Peptide Works

The two peptides act through complementary but distinct mechanisms, which is precisely why they are stacked.

• ✓CJC-1295 (with DAC): Long-acting GHRH analog, half-life ~8 days. Maintains elevated GH baseline between pulses. Typically dosed 1-2x per week.
• ✓CJC-1295 (without DAC / Mod GRF 1-29): Short-acting, half-life ~30 minutes. Produces a sharper, more pulsatile GH release. Dosed daily.
• ✓Ipamorelin: Selective GHRP that mimics ghrelin. Very clean — minimal cortisol and prolactin elevation compared to GHRP-2 or GHRP-6. Half-life ~2 hours.
• ✓Together: The GHRH + GHRP combination is synergistic — producing GH pulses 2-10x larger than either peptide alone.

Common Dosing Protocols

Dosing varies by goal. Always start at the lower end and titrate based on response and IGF-1 levels. These ranges reflect typical clinical protocols — individual dosing should be supervised by a qualified provider.

• ✓Typical Ipamorelin dose: 100-300 mcg per injection, 1-3x daily
• ✓CJC-1295 without DAC (Mod GRF): 100-200 mcg, taken alongside Ipamorelin
• ✓CJC-1295 with DAC: 1-2 mg 1-2x per week (allows less frequent dosing)
• ✓Best timing: 30-60 minutes before bed or first thing in the morning on an empty stomach — glucose blunts GH release
• ✓Typical cycle length: 12-16 weeks, followed by a 4-8 week break

Expected Benefits and Timeline

Results accumulate progressively. Most users begin noticing sleep changes within the first 1-2 weeks, with body composition changes becoming apparent by weeks 8-12.

• ✓Weeks 1-2: Improved deep sleep quality, more vivid dreams, increased energy upon waking
• ✓Weeks 3-4: Mild fat loss beginning, improved recovery from exercise, reduced soreness
• ✓Weeks 6-8: Noticeable body composition changes — reduced visceral fat, slight increase in lean mass
• ✓Weeks 10-16: Continued fat loss and muscle preservation, improved skin quality, enhanced libido in some users
• ✓IGF-1 levels typically rise 20-40% above baseline during active protocol

Who Is This Stack Best For?

CJC-1295 + Ipamorelin is a versatile stack appropriate for a wide range of clinical goals. It is particularly well-suited for adults over 35 whose natural GH production has begun to decline.

• ✓Adults seeking anti-aging and body recomposition without anabolic steroids
• ✓Athletes or active individuals wanting improved recovery and injury healing
• ✓Patients with diagnosed adult growth hormone deficiency
• ✓Those struggling with poor sleep quality and low energy despite normal thyroid and testosterone labs
• ✓Individuals with elevated visceral fat who have not responded adequately to diet and exercise alone

Side Effects and Safety Considerations

CJC-1295 + Ipamorelin is considered one of the safer peptide stacks, with a favorable side effect profile compared to exogenous HGH. The most common side effects are mild and transient.

• ✓Water retention: Common in the first 2-4 weeks, typically resolves with dose adjustment
• ✓Tingling or numbness: Usually in hands and fingers (carpal tunnel-like), often improves with dose reduction
• ✓Fatigue or grogginess: Can occur if peptides are injected too close to waking hours
• ✓Hunger increase: Ipamorelin has mild ghrelin-mimicking effects — manageable with meal timing
• ✓Not appropriate for: Active cancer or cancer history, pregnancy, untreated insulin resistance, or uncontrolled diabetes — GH can worsen insulin sensitivity at higher doses

Monitoring and Lab Work

Responsible use includes baseline and follow-up lab monitoring. Key markers to track include IGF-1 (target 200-350 ng/mL for most adults), fasting glucose and insulin, and a complete metabolic panel. BioRoot AI can help you interpret your labs in the context of your full symptom picture and identify whether growth hormone optimization is a good fit for your health goals.